RxDoctor Payments Data

Alexander Armstrong, PA

Physician Assistant · Ladson, SCNPI 1881208346

Payments from drug & device makers

$422in general payments, 2019–2025

Across 18 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$167
  • Novartis$70
  • E.r. Squibb & Sons, L.L.C.$32
  • Biotronik Inc.$23
  • United Therapeutics Corporation$23
  • Fisher & Paykel Healthcare Inc$21
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422 in reported general payments places this provider in the 50th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$29,479
Medicare patients
282
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin137$172,621
EliquisApixaban126$166,481
EntrestoSacubitril/Valsartan57$81,063
XareltoRivaroxaban45$48,587
FarxigaDapagliflozin Propanediol30$31,310
Repatha SureclickEvolocumab12$19,359
BrilintaTicagrelor11$10,002
Bumetanide92$2,723
Metoprolol Succinate123$1,864
Valsartan18$1,237
Atorvastatin Calcium90$1,021
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$891
Carvedilol93$885
Losartan Potassium87$770
ClopidogrelClopidogrel Bisulfate76$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$172,621137 claims
PfizerEliquis$13$166,481126 claims
NovartisEntresto$70$81,06357 claims
Johnson & JohnsonXarelto$167$48,58745 claims
AstraZenecaFarxiga, Brilinta$14$41,31241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Ladson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →